Deakin University, The Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Barwon Health, Geelong, Australia.
Centre of Youth Mental Health, Department of Psychiatry, University of Melbourne, Parkville, Australia.
Int J Neuropsychopharmacol. 2022 May 27;25(5):387-398. doi: 10.1093/ijnp/pyac014.
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity is implicated as a moderator of the progression of multiple diseases and disorders in medicine and is actively subject to investigation as a therapeutic target. Here we summarize the mechanisms of the enzyme and detail the novel agents under investigation. Such agents modulate peripheral cortisol and cortisone levels in hypertension, type 2 diabetes, metabolic disorders, and Alzheimer's disease models, but there is mixed evidence for transduction into symptom management. There is inchoate evidence that 11β-HSD1 modulators may be useful pharmacotherapies for clinical improvement in psychiatry and neurology; however, more research is required.
11β-羟甾类脱氢酶 1 型（11β-HSD1）活性被认为是多种疾病和障碍进展的调节剂，并且作为治疗靶点受到积极研究。本文总结了该酶的作用机制，并详细介绍了正在研究的新型药物。这些药物可调节高血压、2 型糖尿病、代谢紊乱和阿尔茨海默病模型中的外周皮质醇和皮质酮水平，但对症状管理的转导证据不一。有初步证据表明，11β-HSD1 调节剂可能对精神病学和神经病学的临床改善有用，但仍需更多研究。
Zotero 插件